TY - JOUR T1 - Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone JF - Anticancer Research JO - Anticancer Res SP - 157 LP - 165 DO - 10.21873/anticanres.16145 VL - 43 IS - 1 AU - TAKESHI YOROIDAKA AU - TAKESHI YAMASHITA AU - RYOICHI MURATA AU - KYOKO YOSHIHARA AU - SATOSHI YOSHIHARA AU - MIKIO UEDA AU - SHINJI NAKAO AU - KOSEI MATSUE AU - HIROYUKI TAKAMATSU Y1 - 2023/01/01 UR - http://ar.iiarjournals.org/content/43/1/157.abstract N2 - Background/Aim: Carfilzomib, lenalidomide, and dexamethasone (KRD) therapy is widely used for patients with relapse/refractory multiple myeloma (RRMM). However, the response in patients who underwent assessment for measurable residual disease (MRD) has not been elucidated in a prospective study. We aimed to clarify the response rate and outcome of KRD therapy in patients in RRMM, including those with MRD. Patients and Methods: Twenty-one consecutive RRMM patients treated with KRD at 4 Japanese Centers between September 2016 and October 2018 were enrolled and assessed for MRD in the bone marrow (cut-off: 1×10−5) using the EuroFlow-next-generation flow (NGF) method. Results: The median number of therapy lines before KRD was 3 (range=1-6), and the median number of KRD cycles was 4 (range=1-22). As the best overall response post-KRD therapy, 52% (11/21) of patients achieved a MRD negative complete response, 71% (15/21) achieved stringent complete response/complete response, and 14% (3/21) achieved a very good partial response. MRD negativity was achieved in 12 of 16 (75%) and 14 of 21 (67%) patients during and after KRD treatment, respectively. The 2-year progression-free survival and overall survival from the start of KRD therapy were 100% and 100%, respectively, in MRD-positive cases and 88% and 100%, respectively, in MRD-negative cases (median follow-up=1.8 years). Grade 3/4 toxicities were reported in 15 patients (71%), with thrombocytopenia being the most frequent toxicity (6 patients, 29%). Conclusion: This is the first study that prospectively assessed MRD of patients with RRMM after KRD therapy. KRD treatment achieved a high MRD negativity rate and good outcomes with manageable toxicities. ER -